Jump to content

AstraZeneca: Zactima benefits lung cancer patients


Recommended Posts

LONDON (MarketWatch) -- Astrazeneca PLC (AZN:astrazeneca plc sponsored adr

News, chart, profile, more

Last: 34.74-2.10-5.70%

AZN 34.74, -2.10, -5.7%) Wednesday said its experimental lung-cancer drug Zactima showed clinical benefits in lung cancer patients in combination with chemotherapy, according to the results of three Phase III studies.

The U.K.-based drugmaker said one large study, named ZODIAC, showed advantages for Zactima in combination with chemotherapy, although a smaller combination in a study called ZEAL did not show statistical significance.

But both combination studies showed that adding Zactima to chemotherapy significantly improved the 'Objective Response Rate' which measure tumor shrinkage, the company said in a statement.

A monotherapy study comparing Zactima, whose generic name is vandetanib, with erlotinib, or Tarceva, a lung-cancer drug made by Roche Holding AG (ROG.VX), did not demonstrate statistical significance in prolonging 'progression free survival' which measures the time during and after treatment when the disease does not get worse.

Company Web site: www.astrazeneca.co.uk


Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.